Your browser is no longer supported. Please, upgrade your browser.
Settings
CUR Neuralstem, Inc. daily Stock Chart
CUR [NASD]
Neuralstem, Inc.
Index- P/E- EPS (ttm)-7.08 Insider Own0.30% Shs Outstand3.52M Perf Week-7.25%
Market Cap6.76M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.28M Perf Month-60.41%
Income-5.90M PEG- EPS next Q- Inst Own1.10% Short Float12.44% Perf Quarter-78.67%
Sales0.30M P/S22.53 EPS this Y72.90% Inst Trans-22.12% Short Ratio5.14 Perf Half Y-81.18%
Book/sh3.58 P/B0.54 EPS next Y- ROA-65.60% Target Price26.00 Perf Year-91.86%
Cash/sh- P/C- EPS next 5Y- ROE-98.80% 52W Range1.62 - 27.40 Perf YTD-69.34%
Dividend- P/FCF- EPS past 5Y38.10% ROI-137.70% 52W High-93.25% Beta1.82
Dividend %- Quick Ratio3.80 Sales past 5Y18.80% Gross Margin- 52W Low14.20% ATR0.52
Employees6 Current Ratio3.80 Sales Q/Q-96.90% Oper. Margin- RSI (14)28.72 Volatility13.64% 10.30%
OptionableYes Debt/Eq0.00 EPS Q/Q-20.40% Profit Margin- Rel Volume2.26 Prev Close1.92
ShortableYes LT Debt/Eq0.00 EarningsAug 21 BMO Payout- Avg Volume79.31K Price1.85
Recom- SMA20-20.34% SMA50-62.44% SMA200-77.23% Volume148,387 Change-3.65%
Nov-07-16Initiated Aegis Capital Buy
Aug-29-16Initiated ROTH Capital Buy $1.20
Apr-28-15Initiated MLV & Co Buy $6
Feb-18-15Initiated Brean Capital Buy $8
Sep-08-14Initiated H.C. Wainwright Neutral
Jun-25-14Reiterated Aegis Capital Buy $6 → $7
Dec-10-12Reiterated Aegis Capital Buy $3 → $3.50
Aug-23-12Initiated Maxim Group Sell $0.25
Sep-22-11Initiated Morgan Joseph Buy $5
Aug-14-19 07:30AM  Neuralstem Reports Second Quarter 2019 Fiscal Results PR Newswire
Aug-07-19 11:27AM  Germantown biopharma regains compliance with Nasdaq American City Business Journals
07:30AM  Neuralstem Announces Nasdaq Hearings Panel Grants Request For Continued Listing PR Newswire
Jul-31-19 07:30AM  Neuralstem Closes $7.5 Million Underwritten Public Offering PR Newswire
Jul-29-19 11:33AM  Penny Stocks to Buy Using Technical Analysis for August 2019 Investopedia -7.95%
Jul-25-19 10:40PM  Neuralstem Announces Pricing of $7.5 Million Underwritten Public Offering PR Newswire -25.60%
Jul-18-19 07:30AM  Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of Directors PR Newswire
Jul-16-19 07:30AM  Neuralstem Announces a 1-for-20 Reverse Stock Split PR Newswire +8.32%
Jul-09-19 01:39PM  Germantown stem cell therapy company proposes $7M offering amid delisting threat American City Business Journals
Jul-01-19 04:30PM  Neuralstem Announces Publication of Results from Phase 1 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Patients PR Newswire
Jun-03-19 02:55PM  Germantown biopharma stock on the brink of delisting American City Business Journals
May-16-19 07:07AM  Neuralstem Announces Issuance of New Patent Covering Broad Therapeutic Use of Neural Stem Cells PR Newswire
May-14-19 04:30PM  Neuralstem Reports First Quarter 2019 Fiscal Results PR Newswire +9.81%
May-06-19 07:00AM  Neuralstem Appoints David J. Mazzo, Ph.D., to Board of Directors PR Newswire
Apr-29-19 10:02AM  Some Neuralstem (NASDAQ:CUR) Shareholders Have Copped A 99% Share Price Wipe Out Simply Wall St. +5.99%
Mar-22-19 04:30PM  Neuralstem Reports Year End 2018 Fiscal Results GlobeNewswire -7.12%
Feb-07-19 07:00AM  Neuralstem to Expand Pipeline as Part of Aggressive Growth Effort PR Newswire
Dec-18-18 07:00AM  Neuralstem Appoints Ken Carter, Ph.D., as Executive Chairman of the Board GlobeNewswire
Dec-04-18 05:00AM  Germantown biotech faces stock delisting threat American City Business Journals
Nov-27-18 10:22AM  How Financially Strong Is Neuralstem Inc (NASDAQ:CUR)? Simply Wall St.
Nov-19-18 07:55AM  Market Trends Toward New Normal in Neuralstem, Industrial Services of America, Gulf Resources, Natural Alternatives International, Lifevantage, and Lonestar Resources US Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-14-18 05:00PM  Neuralstem Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Oct-26-18 09:00AM  Neuralstem Announces $2.1 Million Registered Direct Offering GlobeNewswire -27.59%
Oct-25-18 07:00AM  Neuralstem Announces Publication of a Study Showing Benefits of Neural Stem Cell (NSC) Transplantation in a Mouse Model of Alzheimers Disease GlobeNewswire +13.71%
Sep-18-18 11:20AM  Should You Have Neuralstem Incs (NASDAQ:CUR) In Your Portfolio? Simply Wall St.
Aug-15-18 10:24AM  Neuralstem Provides Business Update and Reports Second Quarter 2018 Fiscal Results GlobeNewswire
Aug-09-18 07:00AM  Neuralstem Announces NSI-189 Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Angelman Syndrome GlobeNewswire +12.71%
Aug-07-18 02:41PM  Germantown biopharma Neuralstem appoints interim CEO American City Business Journals
Aug-06-18 07:00AM  Neuralstem Appoints Jim Scully as Interim Chief Executive Officer GlobeNewswire -6.09%
Aug-01-18 09:05AM  CORRECTING and REPLACING -- Neuralstem, Inc. GlobeNewswire
09:01AM  Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial Benzinga
Jul-31-18 06:14PM  Neuralstem Announces Initiation of Phase 2 Clinical Trial of NSI-189 in Ischemic Stroke GlobeNewswire -5.75%
Jul-23-18 11:50AM  Neuralstem Announces Presentation of Preclinical Data Demonstrating Neurogenic Compound NSI-189 Improves Cognition and Anxiety in a Mouse Model of Alzheimers Disease GlobeNewswire +18.80%
Jun-12-18 08:00AM  Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors GlobeNewswire
Jun-11-18 07:00AM  Neuralstem Awarded Phase I SBIR Contract to Support Research into Neural Stem Cell Therapy for Severe Traumatic Brain Injury GlobeNewswire
Jun-04-18 07:00AM  Neuralstems NSI-566 stem cell therapy confers neurological improvement in spinal cord injury patients with complete paraplegia GlobeNewswire
May-29-18 07:00AM  Neuralstem to Participate at the BIO 2018 International Convention GlobeNewswire
May-15-18 07:00AM  Neuralstem Provides Business Update and Reports First Quarter 2018 Fiscal Results GlobeNewswire
May-03-18 07:00AM  Neuralstem Announces Publication of Long-Term Follow-up Data on ALS in the Annals of Clinical and Translational Neurology GlobeNewswire
Apr-18-18 07:00AM  Blog Exposure - Idera Pharma Announces Clinical Development Support Agreement with Pillar Partners Foundation ACCESSWIRE
Apr-11-18 08:30AM  Todays Research Reports on Trending Tickers: Neuralstem and Immunomedics ACCESSWIRE -5.26%
07:00AM  Neuralstem to Present Clinical Update at the Alliance for Regenerative Medicine 6th Annual Cell & Gene Therapy Investor Day GlobeNewswire
Apr-10-18 07:00AM  Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic Spinal Cord Injury GlobeNewswire +11.11%
Apr-02-18 07:30AM  Neuralstem Reports Year End 2017 Fiscal Results and Business Update GlobeNewswire
Mar-13-18 07:00AM  Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury GlobeNewswire
Mar-12-18 07:00AM  Neuralstem to Participate at Upcoming Investor Conferences GlobeNewswire
Feb-08-18 07:00AM  Neuralstem to Participate at The Young Jewish Professionals CEO Healthcare Symposium GlobeNewswire
Jan-22-18 07:00AM  Neuralstem to Participate at Cell and Gene Therapy World GlobeNewswire
Jan-05-18 05:25PM  Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology GlobeNewswire
Dec-26-17 11:25AM  ETFs with exposure to Neuralstem, Inc. : December 26, 2017 Capital Cube
Dec-20-17 07:30AM  New Member appointed to the Board of Directors of Neuralstem GlobeNewswire
Dec-08-17 08:20AM  Todays Research Reports on Trending Tickers: Geron Corporation and Neuralstem, Inc. ACCESSWIRE -10.71%
Dec-07-17 01:26PM  ETFs with exposure to Neuralstem, Inc. : December 7, 2017 Capital Cube +11.44%
Dec-06-17 08:00AM  Todays Research Reports on Stocks to Watch: Neuralstem, Inc. and Biocept Inc. ACCESSWIRE -34.95%
07:53AM  800%+ Revenue Growth Could Imply 200-300% Returns for This Small Cap Stock ACCESSWIRE
Dec-05-17 12:57PM  Neuralstem, Inc. (CUR): Updated Phase II Trial Success in Major Depressive Disorder Takes the Street by Storm SmarterAnalyst +175.89%
07:00AM  Neuralstem Presents Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive Disorder at the 56th American College of Neuropsychopharmacology (ACNP) Annual Meeting GlobeNewswire
Nov-30-17 11:45AM  Does Neuralstem Incs (CUR) Past Performance Indicate A Stronger Future? Simply Wall St.
Nov-16-17 04:05PM  Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting GlobeNewswire +5.15%
Nov-13-17 07:41AM  Neuralstem reports 3Q loss Associated Press -7.27%
07:30AM  Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update GlobeNewswire
Nov-10-17 12:10PM  ETFs with exposure to Neuralstem, Inc. : November 10, 2017 Capital Cube
Nov-09-17 08:59AM  Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 Capital Cube
Nov-08-17 07:30AM  Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer GlobeNewswire
Oct-17-17 05:31PM  One Thing To Consider Before Buying Neuralstem Inc (CUR) Simply Wall St.
Sep-27-17 08:05AM  Neuralstem: Stock falls in July on Phase II Miss, Gets 2 New Patents for Neural Stem Cells ACCESSWIRE -8.57%
Sep-25-17 04:05PM  Neuralstem Announces the Appointment of Two New Members to the Board of Directors GlobeNewswire
Sep-22-17 11:08AM  ETFs with exposure to Neuralstem, Inc. : September 22, 2017 Capital Cube
Sep-11-17 10:28PM  ETFs with exposure to Neuralstem, Inc. : September 12, 2017 Capital Cube
Sep-07-17 09:29AM  Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers TheStreet.com
07:03AM  Neuralstem Announces Issuance of Two U.S. Patents GlobeNewswire
Aug-31-17 05:58PM  ETFs with exposure to Neuralstem, Inc. : August 31, 2017 Capital Cube
Aug-24-17 10:12AM  Neuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-08-17 10:25PM  Neuralstem reports 2Q loss Associated Press
07:30AM  Neuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical and Business Update GlobeNewswire
Aug-02-17 08:30AM  Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy GlobeNewswire
Jul-27-17 08:30AM  Neuralstem Announces Pricing of Public Offering of Common Stock and Warrants GlobeNewswire
Jul-26-17 04:50PM  Neuralstem Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire
08:00AM  Today's Research Reports on Stocks to Watch: Neuralstem and Flex Pharma Accesswire
Jul-25-17 09:09AM  UPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial miss MarketWatch
08:15AM  Neuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive Disorder GlobeNewswire
Jul-04-17 02:51PM  ETFs with exposure to Neuralstem, Inc. : July 4, 2017 Capital Cube
Jun-26-17 08:32AM  Neuralstem Added to the Russell Microcap® Index GlobeNewswire
Jun-02-17 02:00PM  ETFs with exposure to Neuralstem, Inc. : June 2, 2017 Capital Cube
May-23-17 12:36PM  ETFs with exposure to Neuralstem, Inc. : May 23, 2017 Capital Cube
May-17-17 04:05PM  Neuralstem Reports Last Subject Out in Phase 2 Trial of NSI-189 for Major Depressive Disorder GlobeNewswire
May-12-17 10:54AM  Neuralstem, Inc. :CUR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube
May-11-17 04:28PM  ETFs with exposure to Neuralstem, Inc. : May 11, 2017 Capital Cube
08:00AM  Today's Research Reports on Stocks to Watch: MannKind and Neuralstem Accesswire
May-10-17 04:20PM  Neuralstem reports 1Q loss Associated Press
04:05PM  Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update GlobeNewswire
Apr-19-17 02:17PM  ETFs with exposure to Neuralstem, Inc. : April 19, 2017 Capital Cube
Apr-12-17 07:35AM  Neuralstem Expands Phase 1 Safety Trial of NSI-566 Neural Stem Cells in Spinal Injury GlobeNewswire
Apr-05-17 04:35PM  ETFs with exposure to Neuralstem, Inc. : April 5, 2017 Capital Cube
Mar-31-17 08:51AM  NEURALSTEM, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti
Mar-29-17 01:00PM  Neuralstem, Inc. :CUR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017 Capital Cube
10:53AM  Neuralstem, Inc. :CUR-US: Earnings Analysis: 2016 By the Numbers : March 29, 2017
Mar-28-17 01:04PM  NEURALSTEM, INC. Financials
Mar-23-17 03:19PM  NEURALSTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition
07:35AM  Neuralstem Reports Year End 2016 Fiscal Results and Business Update GlobeNewswire
Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. Its lead product candidate is NSI-189, a chemical entity, which has been completed Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical study for the treatment-refractory depression, Angelman Syndrome, Alzheimer's disease, ischemic stroke, diabetic neuropathy, irradiation-induced cognitive deficit, and long-term potentiation enhancement. The company also develops NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease; Phase II clinical trial for the treatment of chronic ischemic stroke; and Phase I clinical trials for the treatment of chronic spinal cord injury, as well as is in preclinical study for the traumatic brain injury. In addition, it develops NSI-532, which is in preclinical study for treatment of Alzheimer's disease; and NSI-777 that is in preclinical study for treatment of human demyelinating diseases. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.